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In a trial of streptokinase versus recombinant tissue.type plasmi. 
nogen activator (rt·PA) for a first myocardial infarction, 270 
patients were randomized. Regional left ventricular function was 
assessed in 214 patients at 3 weeks. The infarct·related artery was 
the left anterior descending artery in 78 patients, the right 
coronary artery in 122 and a dominant left circumflex artery in 
14. Analysis was by the centerline method with a novel correction 
for the area of myocardium at risk, whereby the search region was 
determined by the anatomic distribution of the infarct·related 
artery. 
Infarct·artery patency at 3 weeks was 73% in the streptokinase 
group and 71% in the rt-PA group. Global left ventricular 
function did not differ between the two groups. Mean chord 
motion (± SD) in the most hypokinetic half of the defined search 
region was similar in the streptokinase and rt·PA groups (-2.4 ± 
1.5 versus -2.3 ± 1.3, P = 0.63). There were no differences in 
hyperkinesia of the noninfarct zone. Compared with conventional 
Thrombolytic therapy is clearly indicated in threatened 
acute myocardial infarction; the efficacy of streptokinase 
(1,2), recombinant tissue-type plasminogen activator (rt-PA) 
(3) and anistreplase (APSAC) (4) have been demonstrated in 
controlled mortality trials. Current studies are attempting to 
determine if a particular thrombolytic agent provides greater 
patient benefit, and to establish optimal adjunctive therapy. 
Tissue plasminogen activator appears to be more effec-
tive than streptokinase in achieving early recanalization of 
the infarct-related artery (5,6), but this difference has not 
been proved to produce measurable clinical benefit. The 
GISSI-2 trial (7) showed no difference between rt-PA and 
streptokinase for a combined endpoint of mortality and 
severe left ventricular impairment, and the larger Interna-
tional Study Group trial (8) showed no difference in hospital 
mortality between the two agents. 
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centerline analysis, regional wall motion in the defined area at risk 
was significantly more abnormal. The two methods correlated 
strongly, however (r = 0.99, p < 0.0001), and both methods 
produced similar overall results. 
Patients with a patent infarct·related artery and those with an 
occluded artery at the time of catheterization had similar levels of 
global function (ejection fraction 58 ± 12% versus 57 ± 12%, P = 
0.58). Regional function was also similar in patients with a patent 
and an occluded infarct-related artery on univariate analysis 
(-2.3 ± 1.5 versus -2.6 ± 1.1 SD, p = 0.14), but multivariate 
analysis correcting for variation due to infarct site showed that a 
patent infarct artery was associated with improved regional 
function (p = 0.007). 
Streptokinase and rt-PA in the doses given have similar effects 
on global and regional left ventricular function measured 3 weeks 
after a first myocardial infarction. 
(J Am Coil CardioI1991;17:1039-46) 
Left ventricular function has consistently been shown to be 
the most important prognostic factor after myocardial infarc-
tion, both currently and in the years before thrombolytic 
therapy was available (9-12). Studies generally show better 
preservation of left ventricular function with thrombolytic 
therapy compared with placebo (13-21). We previously re-
ported (22) that global left ventricular function measured 3 
weeks after initial myocardial infarction was identical in pa-
tients treated with streptokinase and rt-PA followed by early 
intravenous heparin. This report presents results of left ven-
tricular regional wall motion analysis in patients randomized to 
receive streptokinase or rt-PA in that study. 
Variable changes in the function of the noninfarct zone 
may reduce the accuracy with which global ejection fraction 
represents infarct zone hypokinesia (23). Most of the vari-
ability in infarct size in canine models of acute infarction is 
due to variation in the anatomic area at risk (24). Failure to 
correct for differences in the extent of myocardium supplied 
by the infarct-related artery may limit the ability to detect 
biologically important differences in myocardial salvage pro-
duced by different agents. We therefore used a novel modi-
fication of the centerline method to assess regional wall 
motion corrected for the area of myocardium at risk. 
0735-1097/911$3.50 
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Methods 
Study patients. Two hundred seventy patients with a first 
myocardial infarction were randomized in a double blind 
trial of rt-PA versus streptokinase. The primary end point 
was global ejection fraction measured by contrast ventricu-
lography 3 weeks after infarction (22). 
All patients were enrolled within 3 h of the onset of 
typical ischemic chest pain of 2:30 minutes' duration. The 
following electrocardiographic (ECG) criteria were required 
in two or more leads: ST segment elevation of 2:0.1 m V in 
the limb leads or leads V 4 to V 6 or 2:0.2 m V in leads V I to 
V3• Patients with left bundle branch block were excluded. 
Patients older than 70 years, those with a history of myocar-
dial infarction, and those with a specific contraindication to 
thrombolytic therapy were not randomized. Specific con-
traindications to thrombolysis included previous cerebrovas-
cular accident, documented peptic ulceration within 6 
months, hypertension (systolic pressure >200 mm Hg), a 
history of hemorrhagic diathesis or current oral anticoagu-
lant therapy, history of urinary tract bleeding, and surgery or 
significant trauma in the preceding 2 weeks. Patients with 
cardiogenic shock were included. All patients gave written 
informed consent, and the study was approved by the ethics 
committees of the four participating hospitals. 
Treatment protocol. Patients were randomized to receive 
either rt-PA (10 mg bolus, 50 mg 1st hand 40 mg over the 
next 2 h) or streptokinase (1.5 million U over 30 min) by a 
double-blind, double dummy technique. A combination of 
aspirin, 25 mg, and dipyridamole, 200 mg (Assasantin, 
Boehringer Ingelheim), was administered orally at the start 
of thrombolytic therapy and continued twice daily. This dose 
of aspirin was chosen with the aim of effectively inhibiting 
platelet cyclooxygenase with relative preservation of endo-
thelial prostacyclin production (25), although we have sub-
sequently adopted a dose of 150 mg/day in view of the results 
of the ISIS-2 trial (2). Heparin infusion was begun 30 min 
after the beginning of blinded thrombolytic infusion and 
continued for 48 h. The initial dose was 1,000 U/h with 
subsequent dose adjustments to maintain the activated par-
tial thromboplastin time within the range of 90 to 110 s. 
Beta-adrenergic blocking therapy was begun on the 3rd 
hospital day in patients without contraindications. 
Cardiac catheterization. Coronary angiography and left 
ventriculography were delayed until 3 weeks after infarction 
to minimize the effects of myocardial stunning (26). Left 
ventricular volumes were calculated from the 30° right 
anterior oblique ventriculogram by an integration method 
with correction factors based on a comparison between true 
and calculated volumes of radiopaque left ventricular casts 
made from hearts at autopsy (27). The infarct-related coro-
nary artery was identified by correlating the coronary anat-
omy with the site of ST elevation on the admission ECG and 
the distribution of impairment of contractility in the biplane 
left ventriculogram. Patency of the infarct-related artery was 
classified according to the criteria of the TIMI trial (6). 
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Figure 1. Regional wall motion analysis in a patient with inferior 
myocardial infarction. The diagram on the left shows the 100 chords 
and that on the right shows the fitted centerline. Arrows indicate the 
region supplied by the right coronary artery (chords 62 to 80). The 
window for conventional centerline analysis of an isolated right 
coronary infarct (chords 51 to 80) is also shown. The area at risk 
method has targeted the region of severe hypokinesia. 
Regional wall motion analysis: centerline method. Re-
gional wall motion was analyzed by the centerline method 
(28), with modification to correct for the area of myocardium 
at risk. As for left ventricular volume estimation, the end-
systolic and end-diastolic contours of well opacified ventri-
cle during sinus rhythm in the 30° right anterior oblique 
projection were traced onto paper and subsequently entered 
into a computer with an X -Y digitizer. Ventriculograms were 
filmed at 50 frames/s and a grid filmed at the level of the 
patient's heart was used for calibration. No attempt was 
made to correct for rotational changes, as such corrections 
increase rather than decrease variability (29). 
The computer generated the centerline between the sys-
tolic and diastolic contours and 100 equally spaced chords 
were drawn perpendicular to the centerline (Fig. 1). Chord 1 
was drawn at the intersection of the aortic contour and the 
anterobasal left ventricular wall and chord 100 at the junc-
tion of the left ventricular contour and the posterior aortic 
contour. The measured motion of each chord was normal-
ized for heart size by dividing by the length of the end-
diastolic perimeter, and normalized motion for each chord 
then expressed in terms of standard deviation units (SD) 
above or below normal mean motion of that chord (Fig. 2). 
Normal chord motion for our laboratory was derived from 
ventriculograms of 52 patients with normal left ventricular 
function and no coronary artery or valvular disease. 
The area of myocardium at risk was defined as the area 
depicted on the 30° right anterior oblique ventriculogram 
supplied by the infarct-related coronary artery. For the 
purposes of this analysis patients with infarction apparently 
caused by a nondominant circumflex coronary artery lesion 
were excluded. Wall motion in these patients is better 
assessed on the left anterior oblique ventriculogram, and 
changes in nonischemic zone function may confound inter-
pretation of a non dominant circumflex territory infarct as 
viewed on the right anterior oblique ventriculogram (30). A 
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Figure 2. Same patient as in Figure 1, with inferior myocardial 
infarction. Normalized chord motion (top) and chord motion ex-
pressed in standard deviations from normal (bottom). Region AD 
(chords 10 to 80) is analyzed. BD represents the search area for 
conventional centerline analysis and CD the area at risk search 
region. The cross·hatched bar is the most hypokinetic 50% of the 
standard search area, and the smaller, diagonally hatched bar the 
most hypokinetic 50% of the area at risk. 
dominant circumflex coronary artery was analyzed as a right 
coronary artery. The proximal limit of the area at risk was 
taken from the "culprit" lesion, defined as either the lesion 
associated with thrombus or the most proximal severe 
stenosis. The distal limit of the area at risk was defined as the 
termination of the infarct-related artery as viewed in right 
anterior oblique projection. The proximal and distal limits 
were marked on the diastolic contour and the chords encom-
passed were described as "at risk." As is usual in centerline 
analysis, chords 1 to 9 and 81 to 100 were excluded from 
analysis because they reflect movement of the aortic root 
and mitral valve, respectively. 
A sliding window half the length of the area at risk was 
used to assess mean chord motion in the most hypokinetic 
half of the area at risk. The computer automatically posi-
tioned the window by testing all possible fits and selecting 
that in which mean hypokinesia was greatest. We also 
calculated mean hypokinesia across the entire search area by 
dividing the sum of hypokinesia of all hypokinetic chords in 
the area by the total number of chords in the search region. 
In addition to analyzing mean chord motion in both the total 
area at risk and the most hypo kinetic half, the circumferen-
tial extent of wall motion abnormality was determined by 
quantifying the percent of chords within the area at risk with 
motion that deviated from the mean by specified quanta. We 
measured the percent of chords with motion> 1, 2 and 3 SD 
below normal. The circumferential extent of akinesia was 
calculated as the percent of chords in the search region with 
normalized motion ~O. 
Hyperkinesia was examined in those chords supplied by 
the artery not implicated in the index infarct. Mean hyper-
kinesia was calculated as the sum of hyperkinesia in all 
hyperkinetic chords subtended by the noninfarct artery 
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divided by the total number of chords in the noninfarct 
region (regardless of their motion). 
In addition to the area at risk analysis, the ventriculo-
grams were analyzed by the conventional centerline method 
by using a sliding window 50% of the length of the assumed 
territory of the infarct artery, defined as chords 10 to 66 for 
a left anterior descending artery infarct and chords 51 to 80 
for a right coronary or dominant circumflex artery infarct 
(28). The primary end point, as in the area at risk analysis, 
was mean chord motion in the most hypo kinetic half of the 
search region. Mean hypokinesia of the total search region 
was also calculated by dividing the summed hypokinesia of 
all hypo kinetic chords in the area by the length of the search 
area (57 chords for a left anterior descending infarct and 30 
chords for a right coronary infarct). Hyperkinesia was sim-
ilarly assessed by summing the degree of hyperkinesia of all 
hyperkinetic chords in the territory of the other artery 
(chords 67 to 80 for an anterior descending infarct and 
chords 10 to 50 for a right coronary infarct) (28), and dividing 
by the length of the noninfarct search region. 
All analyses were performed without knowledge of treat-
ment allocation or patient outcome. 
Statistical considerations. Effects of single classifying 
variables on continuous variables were assessed by one way 
analysis of variance, and the influence of classifying varia-
bles and their interaction (such as the effects of infarct site, 
thrombolytic therapy and their interaction on regional wall 
motion) was assessed by multifactorial analysis of variance. 
Categorical variables were compared using contingency tao 
ble analysis, with Yates correction for continuity in 2 x 2 
tables. Relations between continuous variables were exam· 
ined by least-squares linear regression. All p values reported 
are 2-tailed, and p values <0.05 for primary end points are 
considered significant. The p values reported in subgroup 
analyses have not been corrected for multiple comparisons. 
Because the subgroup analyses involve six different hypoth-
esis tests, we considered p values <0.008 significant. 
The initial sizing calculations for the trial were designed 
to give 80% power to detect a 4% absolute difference in 
global ejection fraction at (l' = 0.05 (22). The regional wall 
motion analysis has 74% power to detect an absolute differ-
ence of 0.5 SD and 97% power to detect a difference of 0.75 
SD at (l' = 0.05. Values are reported as mean values ± SD. 
Results 
Patient characteristics (Table 1). Two hundred seventy 
patients were randomized to receive either streptokinase or 
rt·PA, of whom 240 had technically satisfactory ventriculo· 
grams at 3 weeks. Among the other 30 patients, 14 withdrew 
from the study, 14 died before ventriculography was per-
formed and 2 had technically inadequate ventriculograms. 
Twenty-six other patients were excluded from the regional 
wall motion analysis because the infarct-related artery was a 
nondominant circumflex vessel. Thus, the final group con-
sisted of 214 patients. The time from onset of chest pain to 
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Table 1. Characteristics of the Patients at Baseline 
Characteristic 
Age (yr) 
Gender (M/F) (%) 
History (%) 
Hypertension 
Diabetes 
Claudication 
Angina 
Smoking 
Previous therapy (%) 
Beta-blocker 
Calcium channel blocker 
Infarct location (%) 
Anterior 
Inferior 
All Patients 
(n = 270) 
Streptokinase rt-PA 
(n = 135) (n = 135) 
56 ± 9 55 ± 9 
79121 81/19 
26 22 
10 10 
3 3 
15 11 
56 55 
15 11 
5 7 
32 36 
68 64 
F = feminine; M = masculine. 
Patients With Regional 
Wall Motion Analysis 
(n = 214) 
Streptokinase rt-PA 
(n = 105) (n = 109) 
55 ± 9 55 ± 9 
83117 82/18 
23 23 
10 9 
4 4 
11 11 
59 60 
13 12 
4 6 
35 38 
65 62 
initiation of thrombolytic therapy was 2.2 ± 0.6 h in the 
rt-PA group and 2.2 ± 0.7 h in the streptokinase group. 
Global left ventricular function (Table 2). As reported for 
the full group of 240 patients (22), there was no significant 
difference in global ejection fraction or left ventricular 
volumes between streptokinase- and rt-PA-treated patients 
in this subset of 214 patients. The infarct-related artery was 
patent in 73% of patients receiving streptokinase and in 71 % 
of patients receiving rt-PA. 
Area at risk analysis. Mean chord motion (Table 3). 
Mean chord motion in the most hypokinetic half of the area 
at risk was the same in patients treated with streptokinase 
and rt-PA (-2.4 ± 1.5 versus -2.3 ± 1.3, respectively). 
Similarly, mean hypokinesia across the entire area at risk 
was not significantly different between the two groups. Mean 
hyperkinesia in the noninfarct zone was also similar in 
patients treated with streptokinase and rt-PA. 
Analysis of the subgroups of patients with anterior (left 
anterior descending artery distribution) or inferior (right 
Table 2. Results of Coronary Arteriography and Global Left 
Ventricular Function 
Streptokinase rt-PA 
(n = 105) (n = 109) P Value 
Infarct -related coronary artery 
Left anterior descending (%) 35 38 } Right(%) 61 53 0.27 
Dominant left circumflex (%) 4 9 
Infarct-related artery patent" (%) 73 71 0.59 
Global left ventricular function 
End-systolic volume (m!) 62 ± 29 62 ± 32 0.27 
Ejection fraction (%) 58 ± 13 58 ± 11 0.96 
End-diastolic volume (ml) 145 ± 47 153 ± 50 0.26 
"TIMI (Thrombolysis in Myocardial Infarction) grade 2 or 3 flow (6). 
Table 3. Area at Risk Analysis 
Streptokinase 
Left anterior descending (n = 37) 
artery-related infarction 
Mean chord motion" -3.0±1.5 
(worst 50%) 
Mean chord motion -2.4 ± 1.2 
(entire region)t 
Mean hyperkinesia:!: 0.6 ± 0.7 
Right coronary artery- (n = 68) 
related infarction 
Mean chord motion -2.1 ± 1.5 
(worst 50%) 
Mean chord motion -1.7 ± 1.2 
(entire region) 
Mean hyperkinesia 0.5 ± 0.6 
Total group (n = 105) 
Mean chord motion -2.4 ± 1.5 
(worst 50%) 
Mean chord motion -2.0 ± 1.2 
(entire region) 
Mean hyperkinesia 0.5 ± 0.6 
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rt-PA p Value 
(n = 41) 
-3.1 ± 1.0 0.58 
-2.5 ± 0.9 0.51 
0.4 ± 0.6 0.25 
(n = 68) 
-1.8 ± 1.3 0.23 
-1.4 ± 1.0 0.11 
0.4 ± 0.4 0.48 
(n = 109) 
-2.3 ± 1.3 0.63 
-1.8 ± 1.1 0.49 
0.4 ± 0.5 0.19 
'Mean motion in most hypokinetic half of area at risk; tmean hypokinesia 
in entire search region; tmean hyperkinesia in distribution of noninfarct-
related artery. Results in standard deviation (SO) units ± SO. 
coronary or dominant circumflex artery distribution) infarc-
tion showed that regional hypokinesia was more marked 
with anterior infarction (mean chord motion - 3.1 ± 1.2 SD 
versus -1.9 ± 1.4 SD, p < 0.000l). Averaged chord motion 
was not significantly different between patients treated with 
streptokinase and rt-PA in either the anterior or inferior 
infarct subgroups. 
Circumferential extent of hypokinesia (Table 4). Overall, 
there was no significant difference in the circumferential 
Table 4. Circumferential Extent" of Wall Motion Abnormalities 
Streptokinase 
Group rt-PA Group p Value 
Left anterior descending artery- (n = 37) (n = 41) 
related infarction 
Akinesia 31 ± 29 29 ± 26 0.74 
~ I SO below mean 75 ± 34 85 ± 21 0.13 
~2 SO below mean 58 ± 36 64 ± 29 0.44 
~3 SO below mean 34 ± 28 34 ± 28 0.92 
Right coronary artery-related (n = 68) (n = 68) 
infarction 
Akinesia 17 ± 28 8 ± 20 0.03 
21 SO below mean 64 ± 40 61 ± 36 0.65 
~2 SO below mean 45 ± 40 34 ± 35 0.08 
~3 SO below mean 18 ± 28 8 ± 19 0.03 
Total group (n = 105) (n = 109) 
Akinesia 22 ± 29 16 ± 24 0.09 
? I SO below mean 68 ± 38 70 ± 33 0.68 
~2 SO below mean 50 ± 39 45 ± 36 0.38 
2::3 SO below mean 23 ± 29 18 ± 26 0.17 
"Percent of chords within the search region with the specified degree of 
hypokinesia. 
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Table 5. Regional Left Ventricular Function Not Corrected for 
Area at Risk 
Streptokinase rt-PA P Value 
Left anterior descending (n = 37) (n = 41) 
artery-related infarction 
Mean chord motion -2.8 ± 1.4 -3.0 ± 1.0 0.47 
(worst 50%)* 
Mean chord motion -2.1 ± 1.1 -2.3 ± 0.8 0.50 
(entire region)t 
Mean hyperkinesia:j: 0.7 ± 0.8 0.6 ± 0.7 0.45 
Right coronary artery- (n = 68) (n = 68) 
related infarction 
Mean chord motion -2.1 ± 1.4 -1.8 ± 1.3 0.23 
(worst 50%) 
Mean chord motion - J.7 ± 1.1 -1.4 ± 1.0 0.14 
(entire region) 
Mean hyperkinesia 0.5 ± 0.6 0.4 ± 0.4 0.44 
Total group (n = 105) (n = 109) 
Mean chord motion -2.3 ± 1.5 -2.2 ± J.3 0.68 
(worst 50%) 
Mean chord motion -1.8 ± 1.1 - J.7 ± 1.0 0.50 
(entire region) 
Mean hyperkinesia 0.6 ± 0.7 0.5 ± 0.5 0.30 
*Mean motion in most hypokinetic half of area at risk; tmean hypokinesia 
in entire search region; :j:mean hyperkinesia in distribution of noninfarct-
related artery. Results in standard deviation units ± SO. 
extent of wall motion abnormality in patients treated with 
streptokinase or rt-PA, although there was a trend toward 
fewer chords being akinetic in the rt-PA group (22 ± 29% 
versus 16 ± 24%, p = 0.09). There was no significant 
heterogeneity of difference between the extent of hypokine-
sia in rt-PA and streptokinase-treated patients in the sub-
groups with anterior and inferior infarction (p > 0.2). A trend 
toward a shorter extent of akinesia and severe hypokinesia 
(2:3 SD below average) in patients treated with rt-PA in the 
subgroup with inferior infarction did not reach statistical 
significance when adjusted for multiple comparisons. 
Uncorrected centerline analysis (Table 5). Regional wall 
motion was also similar in streptokinase and rt-PA groups 
when assessed by the conventional centerline method (mean 
chord motion -2.3 ± 1.5 SD versus -2.2 ± 1.3 SD, 
respectively). Hyperkinesia in the noninfarct regions was 
also similar in the two groups when assessed without cor-
rection for individual variations in coronary anatomy. 
Comparison of the area at risk method with conventional 
centerline analysis. The aim of adjusting the search area 
according to the anatomic distribution of the infarct artery 
was to produce a search window more accurately matched to 
the likely area of hypokinesia, and thus to maximize the 
chance of detecting small differences between the two 
thrombolytic agents. For anterior infarction the resultant 
search area was smaller than that used in conventional 
centerline analysis of one vessel disease in all but one patient 
(median 47 versus 57 chords). The area at risk method for 
inferior infarction produced a median search window of 27 
chords, compared with 30 for the conventional centerline 
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Figure 3. The absolute difference between the results of area at risk 
method and standard centerline analysis versus the number of 
chords in the area at risk search region, for patients with anterior 
infarction. Positive differences represent more abnormal motion by 
the area at risk method. Both the average difference between the 
methods and the scatter are greater for shorter search regions. 
analysis. Thirty-five percent of patients had a search area 
longer than 30 chords, with a maximum of 45 chords (chords 
36 to 80). 
The resultant calculation of mean chord motion was thus 
significantly more abnormal by the area at risk method. This 
was true both for anterior infarction (mean difference 0.15 ± 
0.22 SD units, p < 0.0001) and inferior infarction (mean 
difference 0.03 ± 0.02 SD units, p = 0.008), although the 
rounded results for inferior infarction shown in Tables 3 and 
5 are identical. As expected, considering the analysis invari-
ably included overlapping areas of interest, the correlation 
between mean chord motion assessed by the area-at-risk 
method and conventional centerline method was high 
(r = 0.99, p < 0.0001). 
The differences between the two methods were most 
marked in anterior infarction caused by a short left anterior 
descending coronary artery because the difference between 
the two methods is related to the length of the search 
window used for the area at risk analysis (Fig. 3) (r = -0.57, 
p < 0.0001). 
Effect of infarct-related artery patency (Table 6). Global 
left ventricular ejection fraction was similar in patients with 
a patent infarct-related artery at the time of cardiac cathe-
terization (58 ± 12%) and those with an occluded artery (57 
± 12%). Global function did not differ significantly between 
patients with an open or occluded infarct artery, regardless 
of infarct location. 
Regional hypokinesia assessed by the area at risk method 
was also similar in patients with a patent or occluded 
infarct-related artery on univariate analysis. Subgroup anal-
ysis of patients with inferior infarction showed that regional 
hypokinesia was significantly less severe in patients with a 
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Table 6. Global Ejection Fraction and Regional Left Ventricular 
Function by Area at Risk Method: Analysis According to Infarct 
Artery Patency* 
Patent Infarct Occluded Infarct 
Artery Artery p Value 
Left anterior descending (n = 64) (n = 14) 
artery-related infarction 
Mean chord motion - 3.0 ± 1.1 -3.3±1.8 0.46 
(worst 50%) 
Mean chord motion -2.4 ± 1.0 -2.7 ± 1.3 0.25 
(entire region) 
Mean hyperkinesia 0.5 ± 0.6 0.7 ± 0.8 0.23 
Ejection fraction (%) 54 ± 13 53 ± 17 0.75 
Right coronary artery- (n = 89) (n = 47) 
related infarction 
Mean chord motion -1.7 ± 1.5 -2.4±1.1 0.008 
(worst 50%) 
Mean chord motion -1.4 ± 1.1 -1.9±1.0 0.02 
(entire region) 
Mean hyperkinesia 0.4 ± 0.5 0.5 ± 0.4 0.75 
Ejection fraction (%) 61 ± II 58 ± 10 0.18 
Total group (n = 153) (n = 61) 
Mean chord motion -2.3 ± 1.5 -2.6 ± 1.3 0.14 
(worst 50%) 
Mean chord motion -1.8 ± 1.2 -2.1 ± 1.1 0.15 
(entire region) 
Mean hyperkinesia 0.5 ± 0.6 0.5 ± 0.5 0.42 
Ejection fraction (%) 58 ± 12 57 ± 12 0.58 
*Patent infarct artery defined as TlMI (Thrombolysis in Myocardial 
Infarction) flow grade 2 or 3 (6). Regional function expressed as standard 
deviation units ± SD. 
patent infarct artery (-1.7 ± 1.5) than in those with an 
occluded infarct artery (-2.4 ± 1.1, P = 0.008). Interpreta-
tion of these results is complicated by the fact that mean 
chord motion was more abnormal in patients with an anterior 
infarct (-3.1 ± 1.2) than in those with an inferior infarct 
(-1.9 ± 1.4, P < 0.0001) and that patients with an inferior 
infarct were more likely than those with anterior infarction 
to have an occluded infarct artery (35% versus 18%, p = 
0.014). Multifactor analysis of variance showed that after 
correction for variation attributable to infarct site, a patent 
infarct artery was independently associated with improved 
regional function (p = 0.007). Hyperkinesia of the remote 
region was not affected by infarct artery patency. Analysis 
by the conventional centerline method yielded similar results 
(data not shown). 
Discussion 
Comparison of streptokinase and rt·PA. One of the major 
unresolved issues in the management of acute myocardial 
infarction is whether there are important differences in 
efficacy between the various thrombolytic agents. Although 
the TIMI phase 1 trial (6) and European Cooperative Study 
Group trial (5) showed higher early patency rates after rt-PA 
than after streptokinase, a convincing clinical advantage due 
to this difference has not been demonstrated. 
The GISSI-2 (7) and International Study Group (8) trials 
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showed no difference between the two agents in terms of 
early mortality, excluding with 90% certainty an absolute 
early mortality difference of> 1.5% (at a = 0.01) between 
the two agents as administered in those studies. In addition 
to the current trial, comparative left ventricular function 
data are available from the TIMI phase 1 trial (31,32) and the 
Plasminogen Activator Italian Multicenter Study (PAlMS) 
(33). 
In the TIMI phase 1 study half the patients underwent 
repeat arteriography before discharge and had contrast ven-
triculograms suitable for quantitative analysis (31). In that 
study global ejection fraction and regional wall motion were 
identical in patients treated with streptokinase and rt-PA, 
although more patients in the rt-PA group had both early 
reperfusion and a patent artery at the second angiographic 
study (50% versus 27%, p < 0.01). Most patients (79%) in the 
TIMI phase 1 study also underwent equilibrium radio nuclide 
ventriculography before hospital discharge (32). Again there 
was no difference in global ejection fraction between the two 
treatment groups, although a trend toward better regional 
ejection fraction in the area subtended by the infarct artery 
in patients treated with rt-PA was observed (40% versus 
36%, 0.05 < P < 0.06). 
In PAlMS (33), left ventricular function as assessed by 
contrast left ventriculography was similar in patients treated 
with streptokinase and those treated with rt-PA. Satisfactory 
echocardiograms, obtained in a subset of the patients (68%) 
before discharge, demonstrated a benefit of borderline sta-
tistical significance in favor of rt-PA in terms of global 
ejection fraction, but not for a semiquantitative wall motion 
index. 
The present study, which included only patients with a 
first infarction, also shows that there is little or no difference 
between the two agents in terms of preservation of left 
ventricular function. The trend toward improved regional 
function, as measured by the circumferential extent of wall 
motion abnormality, in patients with inferior infarction 
treated with rt-PA was not statistically significant. In any 
case, the circumferential extent of wall motion abnormality 
is probably a less reliable measure of regional function than 
mean wall motion because the length of the abnormally 
contracting zone may be substantially influenced by tether-
ing from the neighboring "normal" zone (28). 
Delaying heparin therapy until 12 h after thrombolytic 
therapy in the GISSI-2 (7) and International Study Group 
trials (8) may have negated the benefits of the superior early 
reperfusion with rt-PA therapy by allowing early reocclusion 
of the infarct artery. This possibility is being addressed by 
the ongoing ISIS-3 and Global Utilization of Streptokinase 
and t-PA for Occluded Coronary Arteries (GUSTO) studies, 
but it is pertinent that intravenous heparin was administered 
in TIMI phase 1 (6), PAlMS (33) and the current study. 
Advantages of the area at risk method. Targeting the 
search area for regional wall motion assessment to the area 
subtended by the infarct-related artery in each individual 
patient partially controls for one source of variation between 
the two treatment groups. In the conscious dog model of 
JACC Vol. 17, No.5 
April 1991:1039-46 
myocardial infarction, 66% of the variation in infarct size in 
control dogs is attributable to variation in the anatomic area 
at risk (24). 
The results of the area at risk method and conventional 
centerline analysis are strongly correlated, and the overall 
results of this trial are similar by both methods. Mean 
regional wall motion in individual patients is significantly 
more abnormal by the area at risk method, particularly for 
anterior infarction related to a short left anterior descending 
vessel. 
It is not established whether the correction for area at risk 
provides better correlation with other indexes of myocardial 
damage than the standard centerline method, or whether it 
provides independent prognostic information. We believe 
that the method may be particularly useful in smaller trials 
where failure to correct for variation in patterns of coronary 
artery supply may limit the ability to detect important 
differences between treatment groups. 
Effects of infarct-related artery patency. The dissociation 
between late patency of the infarct-related artery and global 
left ventricular function is an unexpected finding. Patients in 
whom early reperfusion occurs should have better late left 
ventricular function due to myocardial salvage. However, 
late changes in infarct-related artery patency are common 
after thrombolytic therapy (31,34), and crossover between 
groups, with an initially blocked artery opening late and vice 
versa, may explain the apparent paradox. 
This result does, however, cast some doubt on the effect 
of late changes in infarct artery patency on left ventricular 
function. It has been suggested that restoration of antero-
grade coronary blood flow beyond the time window when 
myocyte salvage is likely may improve late left ventricular 
function by limiting infarct area expansion and subsequent 
left ventricular remodelling (35-37). If these changes were 
substantial, one would expect that patients with a patent 
artery at 3 weeks (including both those in whom it had been 
opened early and remained patent and those in whom the 
artery achieved late patency) would have better global 
function than those in whom it had never opened or reoc-
cluded later. We did not observe such a difference. 
Conclusions. Regional left ventricular function, assessed 
3 weeks after initial myocardial infarction by a novel modi-
fication of the centerline method with correction for the area 
of myocardium at risk, was similar in patients randomized to 
receive streptokinase or rt-PA. These results provide further 
evidence that despite the fact that rt-PA achieves more rapid 
clot lysis than streptokinase, there does not appear to be a 
substantial difference in terms of preservation of left ventric-
ular function, which is the major predictor of long-term 
survival. 
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